Taking treatment decisions in non-melanoma skin cancer—The place for topical photodynamic therapy (PDT)
Introduction
Epithelial non-melanoma skin cancer (NMSC) like actinic keratosis (AK), Bowen's disease (BD) and basal cell carcinoma (BCC) represent the most common malignancies in the fair skinned population. Epidemiological data reveal high incidences, especially for actinic keratoses, which are basically non-invasive squamous cell carcinomas, but fortunately bear a low risk of mortality for a single lesion. Nevertheless these lesions have to be treated. The appearance of new treatment modalities like immuno-modulating topical agents, topical diclofenac, and photodynamic therapy in addition to a long list of already established treatments (curettage, surgery, cryotherapy, topical 5-fluorouracil (5-FU), and many others) have led to the fact that patients and treating physicians have a large spectrum of therapeutic options to choose from. The same – with some variations – holds true for Bowen's disease and BCC. Aim of this article is to offer an overview over NMSCs as classical indications for PDT, to provide resources for guidelines for the treatment of these diseases, and to position PDT in this context by helping selecting patients that would profit most from topical PDT.
Section snippets
Materials and methods
By combining data from the literature with the (statistically unstructured) clinical experience of an outpatient clinic having about 25,000 patient contacts a year we try to approach the process of decision taking in the treatment of patients with NMSC with emphasis on the value of topical PDT in this context.
Actinic keratosis/carcinoma in situ
Actinic keratoses are cutaneous lesions induced by UV-light and develop mostly in fair skinned patients being susceptible to solar damage [1]. The term actinic keratosis (AK) though, is a source of confusion and ongoing debate. Interpreting the name of these lesions literally bears the danger to wrongly conclude that these sun-induced rough spots are basically benign lesions and little more than cosmetic nuisances (sometimes being confused with seborrhoeic keratoses and other benign lesions).
Recommendations and guidelines
Many recommendations for the treatment of AK and Bowen's disease have been published [2], [26], [30], [34], [38], [53], [54], [55]. They are all mainly based on the evidence level available (see Appendix A) for the different treatment options (Table 1, Table 2). Treatment guidelines for BCCs have been briefly summarized recently by Breuninger et al. [56]. It is clear that in this context the gold standard are randomized controlled trials. For PDT a long list of appropriate trials has been
General aspects in the treatment of NMSC
Although these publications attest PDT an important role in the treatment of NMSC it is remarkable that this therapeutic modality is not being generally offered to patients. This strongly differs from country to country and – within countries – from centre to centre or even from physician to physician. Amongst others, we think that a major reason for this is the fact that in these publications not enough emphasis is put on the fact that the choice of a specific treatment is not a matter of cure
PDT vs. surgery
As has been shown by many clinical studies and our own clinical experience PDT delivers excellent cosmetic results, scarring being an exception and usually not the consequence of the procedure but of the tissue destruction by the original underlying tumour. But the avoidance of scars is not only a cosmetic issue. Depending on the localization surgery bears the risk of functional impairment (e.g. over digital joints), which is rather improbable due to the relative selectivity of the photodynamic
PDT in AKs
A vast list of therapeutic options has been described for the treatment of AK (see Table 1). Some have been used for decades, some have hit the market only recently. Only very few of them have been compared with each other in randomized controlled trials. A comparison of all of them would be neither feasible nor would it make sense especially if AKs would be cumulatively seen as one disease not taking into consideration the variety of clinical appearances and patients’ needs. The approach will
Summary and conclusions
In this overview we tried not to look at the individual disease states, but give a general help for comparing PDT with other treatment methods and emphasizing its position in the treatment of different kinds on NMSC. Even if summarized under the term non-melanoma skin cancer the spectrum of these lesions is very broad. As a consequence there cannot be one single treatment of choice that will be equally suitable for all of these lesions. In addition not only the variability of the lesions but
References (98)
- et al.
The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes
Clin Dermatol
(2004) - et al.
Malignant transformation of solar keratoses to squamous cell carcinoma
Lancet
(1988) - et al.
Actinic keratoses
J Am Acad Dermatol
(1997) - et al.
The different telomere lengths in basal and squamous cell carcinomas also differ between the nontransplant and renal transplant population
Hum Pathol
(2008) - et al.
Cutaneous Bowen's disease. An analysis of 1001 cases according to age, sex, and site
J Am Acad Dermatol
(1992) - et al.
Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery
J Am Acad Dermatol
(2005) - et al.
Bowen's disease (squamous cell carcinoma in situ) in Kauai, Hawaii. A population-based incidence report
J Am Acad Dermatol
(1994) - et al.
The role of the orthodontist in the diagnosis of Gorlin's syndrome
Am J Orthod Dentofacial Orthop
(1999) - et al.
Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light
J Am Acad Dermatol
(2001) Methyl aminolevulinate: actinic keratoses and Bowen's disease
Dermatol Clin
(2007)
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005
J Am Acad Dermatol
Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial
J Am Acad Dermatol
Actinic keratosis: from the skin to the lip
J Oral Maxillofac Surg
Dermabrasion of the scalp as a treatment for actinic damage
J Am Acad Dermatol
Topical treatment of multiple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: a double-blind, comparative study
J Am Acad Dermatol
A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck
J Am Acad Dermatol
Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides
Cancer Lett
Etretinate in treatment of actinic keratosis. A double-blind crossover study
Lancet
Radiation therapy for Bowen's disease: lessons for lesions of the lower extremity
J Am Acad Dermatol
Treatment of Bowen's disease of the digit with carbon dioxide laser
J Am Acad Dermatol
Pathology and pathobiology of actinic (solar) keratosis—an update
Br J Dermatol
Actinic keratosis is squamous cell carcinoma
J Am Acad Dermatol
Guidelines for the management of actinic keratoses
Eur J Dermatol
Solar keratosis is squamous cell carcinoma
Arch Dermatol
Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses
Semin Cutan Med Surg
Histopathology of incipient intraepidermal squamous cell carcinoma (“actinic keratosis”)
J Am Acad Dermatol
The actinic (solar) keratosis: a 21st-century perspective
Arch Dermatol
Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification
Br J Dermatol
The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia)
Br J Dermatol
Epidemiology of solar keratoses
Br J Dermatol
Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation
Br J Dermatol
Multiple actinic keratosis and skin tumors secondary to hydroxyurea treatment
Dermatology
A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications
Cancer Res
The risk of progression to invasive disease
J Am Acad Dermatol
Invasive squamous cell carcinoma of the skin: defining a high-risk group
Ann Surg Oncol
Guidelines for management of Bowen's disease. British Association of Dermatologists
Br J Dermatol
Predictors for cutaneous basal-and squamous-cell carcinoma among actinically damaged adults
Int J Cancer
Guidelines for management of Bowen's disease: 2006 update
Br J Dermatol
Bowen disease and risk of subsequent malignant neoplasms: a population-based cohort study of 1147 patients
Arch Dermatol
Sebaceous carcinoma arising from Bowen's disease of the vulva
Arch Dermatol
Carcinoma arising in Bowen's disease
Arch Dermatol
Basal cell carcinoma
Postgrad Med J
Contribution of stem cells and differentiated cells to epidermal tumours
Nat Rev Cancer
Epidemiology and aetiology of basal cell carcinoma
Br J Dermatol
Lung metastases in a case of metatypical basal cell carcinoma of the eyelid: an illustrative case and literature review to heighten vigilance of its metastatic potential
Clin Experiment Ophthalmol
Variations in clinical presentation of basal cell carcinoma
Acta Clin Croat
Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors
J Cutan Med Surg
Variations of basal cell carcinomas according to gender, age, location and histopathological subtype
Br J Dermatol
Cited by (60)
Exploring the potential of photodynamic therapy in the treatment of non-melanoma skin cancer: Analysis of two clinical cases
2023, Photodiagnosis and Photodynamic TherapySuccessful treatment of giant Bowen's disease with photodynamic therapy and subsequent imiquimod in a case with chronic arsenic exposure
2022, Photodiagnosis and Photodynamic TherapyCitation Excerpt :If left untreated, around 3–5% of cases would progress into invasive SCC [1]. The prognosis of BD is excellent because it responds well to different treatments including surgery or non-surgical interventions such as topical imiquimod, topical 5-fluorouracil, cryotherapy, ablative laser, radiation, and photodynamic therapy (PDT) [2]. However, BD in patients with a history of arsenic exposure usually affects non-exposed areas with multiple lesions, and BD lesions on the acral skin in such patients have the risk of distant metastasis [3].
Radionuclide Therapy of Skin Cancers and Bowen's Disease Using A Specially Designed Rhenium Cream
2022, Nuclear Medicine and Molecular Imaging: Volume 1-4Aminoleveulinate photodynamic therapy (ALA-PDT) for Bowen's disease in a SLE patient: Case report and literature review
2017, Photodiagnosis and Photodynamic TherapyCitation Excerpt :BD, as a form of squamous cell carcinoma in situ, represents an early stage cutaneous malignant neoplasm. The treatment options for BD include surgery, electrodissection, cryotherapy, immune-modulating topical creams (5-fluorouracil and imiquimod), PDT, laser ablation, and radiotherapy [3]. The choice of treatment depends on the patient’s tolerance, the area of the lesion, and the number of lesions.
PDT and emerging therapies for Actinic Keratosis—A resource letter
2017, Photodiagnosis and Photodynamic Therapy